

Size :
W - 70 mm
H - 140 mm

Sucleer™ Gliclazide

Composition:

Sucleer™ 80 Tablet: Each tablet contains Gliclazide BP 80 mg.

Sucleer™ MR Tablet: Each modified release tablet contains Gliclazide BP 30 mg.

Description:

Sucleer™ (Gliclazide) is a 2nd generation sulfonylurea drug which has both hypoglycemic & potentially useful haemobiological properties. It stimulates the release of insulin from pancreatic beta-cells by facilitating Ca²⁺ transports across the beta-cell membranes & decreases hepatic glucose output.

Indications:

Sucleer™ is indicated for the treatment of type 2 diabetes mellitus whose blood glucose cannot be controlled by diet alone.

Dosage & Administration:

Sucleer™ 80: Initially 40-80 mg daily, adjusted according to response; up to 160 mg as a single dose, with breakfast, higher doses divided, max. 320 mg daily.

Sucleer™ MR: Initially 30 mg daily with breakfast, adjusted according to response every 4 weeks (after 2 weeks if not decrease in blood glucose); max. 120 mg daily before breakfast.

OR AS DIRECTED BY THE PHYSICIAN.

Side Effects:

Side effects of sulfonylureas are rare, generally mild, infrequent & include gastrointestinal disturbances such as nausea, vomiting, diarrhea & constipation. There may be hypoglycemia in concurrent conditions such as hepatic & renal disease, headache, allergic reactions, rash, pruritus etc. may occur.

Precautions:

Caution should be exercised in patients having hepatic & renal impairment & a small starting dose should be used with careful patient monitoring. Avoid if creatinine clearance is less than 10 ml/minute.

Pregnancy:

Gliclazide should not be used during pregnancy, because neonatal hypoglycemia may occur. If oral drugs are used to control blood glucose, therapy should be stopped at least 2 days before delivery.

Lactation:

Gliclazide should not be used during lactation period.

Pediatric use:

Not recommended.

Drug Interactions:

Androgens, anticoagulants, chloramphenicol, fluconazole, miconazole, histamine H₂ antagonists, MAO inhibitors: phenylbutazone, probenecid, salicylates, sulfonamides and tricyclic antidepressants may enhance the hypoglycemic effect of Gliclazide. Beta-blockers, rifampicin, thiazide diuretics, thyroid hormones, laxatives and oral contraceptives may decrease the hypoglycemic effect of Gliclazide.

Contraindications:

This drug is contraindicated in patients with known hypersensitivity to Gliclazide or any other components of this preparation. It is also contraindicated in severe hepatic & renal impairment, children, neonates, presence of ketoacidosis, etc.

Storage Condition:

Store in a cool and dry place below 30° C, protect from light. Keep out of the reach of children.

Presentation:

Sucleer™ 80 Tablet: Each box contains 5x10's tablets in blister pack.

Sucleer™ MR Tablet: Each box contains 3x10's tablets in blister pack.

Manufactured by:



RAK Pharmaceuticals Pvt. Ltd.
Gazipur, Bangladesh.

91214033